UNSPSC 51171631: Macrogol or polyethylene glycol

This classification denotes a synthetic polymer with the molecular formula C2H6O2(C2H4O)N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B697894SGQ. European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. The term polyethylene glycol 400 is an International Nomenclature of Cosmetic Ingredients designation.

European Medicines Agency schedules polyethylene glycol 400 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16380MIG. Macrogol or polyethylene glycol bears US NLM identifiers UMLS ID C0032483 and NCI Concept Code C762. SMILES: COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO.

UNSPSC 51171631 Macrogol or polyethylene glycol is a Commodity code that in recent state and local procurement appears to cover reagents and supplies used in drug-testing and specimen-analysis workflows rather than the bulk chemical itself. State and local buyers soliciting under this code include county criminal justice and community supervision agencies performing offender drug screening and confirmation testing. The work involves immunoassay screening supplies, LC/MS/MS or GC/MS confirmation reagents, and ancillary testing materials consumed in high-volume specimen collection and lab analysis operations. Collin County Community Supervision and Corrections Department represents the identified recent issuing body active under this code.

Collin County, Texas is the jurisdiction showing recent activity under this code. The representative opportunity is Collin County's RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, posted September 25, 2026 with a response deadline of July 23, 2026 at 2:00 p.m. The scope encompasses staffing two collection sites in Plano and McKinney, operation of an Interactive Voice Response system for randomized testing notifications, immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, and alternative testing methodologies including oral fluid and hair testing. Annual testing demand is approximately 25,031 tests, comprising 5,452 five-panel screens, 18,006 six-panel screens, and ancillary testing. The estimated contract value is $600,000, with a two-year term commencing September 1, 2026 and three optional one-year renewal periods not to exceed five years total. Pricing shall be submitted on a per-test basis with three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. The successful vendor must maintain lab certification from SAMHSA, TX DPS, or CAP. The anticipated award date is August 10, 2026.